Summary workshop report: Biopharmaceutics classification system—implementation challenges and extension opportunities
Journal of Pharmaceutical Sciences2004Vol. 93(6), pp. 1375–1381
Citations Over TimeTop 10% of 2004 papers
James E. Polli, James E. Polli, Lawrence X. Yu, Jack Cook, Gordon L. Amidon, Ronald T. Borchardt, Beth Burnside, Philip S. Burton, Mei‐Ling Chen, Dale P. Conner, Patrick J. Faustino, Amale Hawi, Ajaz Hussain, Hemant Joshi, Gloria Y. Kwei, Vincent H.L. Lee, Lawrence J. Lesko, Robert A. Lipper, Alice E. Loper, Shriniwas G. Nerurkar, Joseph W. Polli, Joseph W. Polli, Dilip R. Sanvordeker, Rajneesh Taneja, Ramana Uppoor, Chandra S. Vattikonda, Ian R. Wilding, Guohua Zhang
Related Papers
- → The biopharmaceutics classification system (BCS): Class III drugs — better candidates for BA/BE waiver?(1999)145 cited
- → Lipid-Based Nanocarriers for the Oral Administration of Biopharmaceutics(2016)56 cited
- → An Investigation into the Influence of Experimental Conditions on In Vitro Drug Release from Immediate-Release Tablets of Levothyroxine Sodium and Its Relation to Oral Bioavailability(2011)18 cited
- → BIOAVAILABILITY AND BIOEQUIVALENCE STUDY IN CORRELATION OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) AND POSSIBLE MODIFICATION(2013)1 cited
- → Prediction of Negative Food‐Effect on Drug Bioavailability by Mechanistic Biopharmaceutics Classification System (mBCS)‐guided Physiologically‐based Pharmacokinetic modeling(2020)1 cited